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This paper documents the existence of an additional complement regulatory
principle, C4b inactivator . C4b inactivator, which may well be identical to C3b
inactivator, was partially purified from normal human serum and the parameters
of its action upon C4b analyzed, C4b inactivator inactivated the hemolytic and
immune adherence activity of the activated fourth component of complement,
C4b, by direct proteolytic cleavage of the a'-polypeptide chain of the molecule .
A number of other serum proteins have been identified which act at key sites in the
complement sequence to modulate or prevent the progression of the reaction . These
regulatory principles include C1 inactivator, a proteolytic enzyme inhibitor that prevents
activation of the classical complement pathway by forming a complex with the first
complement component and rendering it unable to activate C2 and C4 (1, 2) . Biological
functions of the activated third component of complement, C3b, are modulated by C3
inactivator orKAF, a serum enzyme that cleaves C3b (3, 4) and which may be identical to
C4b inactivator . C3b fragmented by this enzyme is unable to participate in an ongoing
complement reaction, to trigger activation of the properdin pathway, or to interact with
lymphocytes and other cells possessing receptors for C3b . C3b inactivator has also been
postulated to be an inhibitor ofFactorD of the alternative pathway (5) . The chemotactic
and histamine releasing properties of the small cleavage products of C3 and C5, Ma and
C5a, respectively, are rapidly lost due to the action of a serum carboxypeptidase B-type
enzyme termed anaphylatoxin inactivator (6) . Other control proteins have been described
(7-11) but these agents have not yet been characterized . The physiological importance of
the regulatory proteins of the complement system is indicated by the fact that absence of
at least two of them, C1 inactivator and C3b inactivator, leads to uncontrolled activation
of the complement system with accompanying disease (1, 5, 12) .
Materials and Methods
Chemicals and Reagents . Reagent grade sodium phosphate (J . T . Baker Chemical Co.,
Phillipsburg, N . J .), sodium barbital (Sigma Chemical Co., St . Louis, Mo.), Tris (Sigma Chemical
Co .), and sodium acetate (Mallinckrodt Chemical Works, St . Louis, Mo .) were used to prepare
buffers . Phenyl methyl sulfonyl fluoride (PMSF) ` and diisopropyl fluorophosphate (DFP) were
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purchased from Calbiochem, San Diego, Calif . and Boots Pure Drug, Ltd., Nottingham, England,
respectively . Agarose was obtained from Marine Colloids Inc ., Springfield, N. J . and ion agar from
CoLab, Inc ., Glenwood, 111 . Sodium dodecyl sulfate (SDS) was obtained from Sigma Chemical Co .
and dithiothreitol (DTT) from Bio-Rad Laboratories, Richmond, Calif . The composition of
barbital-buffered saline containing 1 .5 x 10-M calcium, 5 x 10-'M Mg, and0.1% gelatin (GVB)
hasbeen described (13) . Tris-buffered saline wascomposed of 5 x 10 -'M Tris and 1 x 10-'MNaCl,
pH 7 .5 .
Soybean, lima bean, and ovomucoid trypsin inhibitors were purchased from Worthington
Biochemical Corp ., Freehold,N. J ., kallikrein-trypsin inhibitor (Trasylol) wasobtained throughthe
courtesy of Dr . Schmidt-Kastner, Bayer AG, Elberfeld, Germany . Marker proteins employed for
molecular weight determinations included reduced a,-macroglobulin (185,000) kindly provided by
Dr . Peter C. Harpel, (New York Hospital-Cornell Medical Center, New York) reduced R-galactosi-
dase (135,000) obtained from Worthington Biochemical Corporation, Freehold, N . J., reduced
phosphorylase A (94,000) from Sigma Chemical Co ., reduced fibrinogen (70,900, 40,400, 49,400)
kindly provided by Dr . Michael Mosesson (Downstate Medical Center, State University ofNewYork,
Brooklyn ; N . Y.), reduced glyceraldehyde-3-phosphate dehydrogenase (36,000) obtained from
Worthington Biochemical, and reduced chymotrypsinogen (25,500) obtained from Calbiochem .
Isolated C1 inactivator, a,macroglobulin, a,-antitrypsin, and partially purified inter-a-trypsin
inhibitor were kindly provided by Dr . Peter C. Harpel . Bovine conglutinin was isolated by themethod
of Lachmann (14) .
Complement and Complement Reagents .
￿
Fresh human serum was employed for the isolation of
Cl, Cls, C2, C4, C3, and C4b inactivator . Cls was isolated by a modification (2) of the previously
published method (15) . C1 (16), C2 (17), C3 (18), and C4 (19) were isolated as described . C2 was
exclusively in the oxidized form (20) . The cellular intermediates EAC1 (16), EAC14 (17), and
EAC1423 (21) were prepared by published methods .
Preparation of Forssman Antigen-Antibody-Complement Complexes .
￿
Sheep erythrocyte mem-
brane fragments containing Forssman antigen (F) were prepared as described by Rapp and Borsos
(22) . The particles were sensitized with Forssman antibody, C1, and [' 251]C4 as previously described
(19) .
Isolation of C4b Inactiuator .
￿
ForDE-32 cellulose chromatography, approximately 400 ml of fresh
normal humanserum was adjusted topH 7.5 with HCland dialyzed in the cold against 10 liters ofthe
starting buffer which wascomposed of 1 x 10-'M Tris, 2 x 10 -'M EDTA, pH 7.5, conductance 1.2
mmhos/cm (all conductivity measurements were performed at 22°C) . After removal from the small
precipitate, the supemate was applied to a9 x 60 cm column ofDE-32 cellulose equilibrated with the
same buffer . Next, a 2 liter wash was applied followed by a 6 liter NaCl gradient to a limit
concentration of 20 mmhos/cm . Fractions containing the peak of C4b inactivator activity were
pooled, concentrated by ultrafiltration (Amicon Corp ., Lexington, Mass .) to 100 ml and dialyzed
against the starting buffer for CM-32 cellulose chromatography . This buffer wascomposed of 1 x 10-2
M sodium acetate, 2 x 10-'M EDTA, pH 6.0, conductance 1.1 mmhos/cm . Thesample was applied
to the column, followed by a l liter wash of starting buffer and a 2 liter linear NaCl gradient to a limit
concentration of 20 mmhos/cm . The pool of active material was concentrated by ultrafiltration to 50
ml and dialyzed against the starting buffer for hydroxyl apatite chromatography which was 1 x 10,-2
M sodium phosphate, pH 7.9, conductance 2.3 mmhos/cm . The sample was applied to a 2.8 x 30 cm
column of hydroxyl apatite, followed by a 500 ml wash of starting buffer and a 2 liter gradient
composed of 1 liter of starting buffer and 1 liter of sodium/potassium phosphate buffer having apH of
7.9 and a conductance of 25 mmhos/cm . The limit buffer was prepared by addition of 6.5 x 10-'M
potassium phosphate, pH 7.9 to 1 x 10-2M sodium phosphate, pH 7.9 to the desired conductance .
The active material eluting from thecolumn was concentrated by ultrafiltration to 2ml and frozen in
aliquots at -70°C .
Measurement of Protein Concentration .
￿
Protein was measured by theLowryprocedure (23), with
C3 as a reference standard .
Immunochemical and Electrophoretic Analyses . Immunoelectrophoresis was performed in 1%
agarose in a barbital buffer (pH 8.6) containing 1 x 10-z M EDTA . Polyacrylamide disc
electrophoresis in 6% running gels was performed by the method of Davis (24) in Tris-HCl-glycine
buffer, pH 8.7 .
SDS-Polyacrylamide Gel Electrophoresis .
￿
Analyses to determine the molecular weights of C4892
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and its cleavage fragments were performed in 7% polyacrylamide gels containing 0.1% SDS in
phosphate buffer, pH 7.25, according to the method of Weber and Osborn (25), as modified by Harpel
and Mosesson (26) . 1 vol of protein solution was mixed with 1 vol of phosphate buffer containing 8.5
M urea, 2% SDS, and where indicated, 1 .4 x 10- z MDTT . After an incubation of45 min at 37°C, an
equal vol of 50% glycerol and water saturated with bromophenol blue was added and 25-J1 samples
applied to 6 x 80 or 6 x 130 mm gel columns and electrophoresed for 3 h at 8 mA per gel in a Hoefer
gel electrophoresis apparatus (Hoefer Scientific Instruments, San Francisco, Calif .) . The electropho-
resis buffer was 1 x 10- ' M sodium phosphate, pH 7.25, containing 0.1% SDS . Gels were stained first
with Amido Schwartz followed by Coomassie blue . When radiolabeled C4 was employed the gels were
sectioned immediately after electrophoresis at 2-mm intervals and the sections analyzed for
radioactivity in a Packard auto -y-scintillation spectrometer (Packard Instrument Co ., Inc ., Downers
Grove, Ill .) .
Sucrose Gradient Ultracentrifugation .
￿
Samples were sedimented in 7-31% linear sucrose density
gradients prepared in barbital-buffered saline, pH 7 .3, in an SW-50 rotor at 40,000 rpm for 18 h in a
Beckman L-250 ultracentrifuge (Beckman Instruments, Inc ., Spinco Div, Palo Alto, Calif.) . An ionic
strength of 0.15 was maintained throughout the gradient . Marker substances were included in
separate tubes .
Radiolabeling ofPurified C4 .
￿
Isolated C4 was radiolabeled with "'I by the method of McConahey
and Dixon (27) as has been described for C4 (19) .
Generation of C3b and Cob .
￿
Isolated C3 was incubated with 2% trypsin (wt/wt) for 5 min at 37°C .
Trypsin was neutralized with a twofold excess of soybean trypsin inhibitor and the mixture subjected
to electrophoresis in a Pevikon block at pH 8 .6 . Eluates of the block, which had the ability to induce
consumption ofC3 on addition to serum were pooled at C3b . Isolated C4b was incubated with a 1 :10
molar ratio of isolated Cls for 30 min at 37°C . Verification of C3b and C4b formation was demon-
strated by hemolytic measurement which indicated that greater than 99% of the activity of each pro-
tein had been lost.
Measurement of C3 and C4 Hemolytic Activity . The hemolytic activity of C3 and C4 was
measured by effective molecule titration (16, 21) .
Measurement of C3 and C4 Immune Adherence Activity .
￿
Immune adherence activity of bound
C4 was assessed by the microtiter method employing dilutions of EAC14 with human type 0, Rh
erythrocytes as indicator particles (28) .
Results
Isolation of C4b Inactivator.
￿
The method employed for partial purification of
C4b inactivator was adapted from that published by Lachmann for C3b
inactivator (3) . Initial separation of whole serum into euglobulin and pseudo-
globulin fractions was avoided during the isolation procedure since C4b inactiva-
tor is present in both fractions . As shown in Fig. 1, fractions from two distinct
areas of the chromatogram had the ability to inhibit C4b-dependent immune
adherence . Fractions from both areas also inhibited C3b-dependent immune
adherence . The first peak of activity emerged from the column just before, and
overlapping with C3 proactivator and transferrin in fractions having a conduct-
ance of 5.5-7 mmhos/cm . The second area of the column having the ability to
inhibit C4b immune adherence correlated with the appearance of C3 from the
column . This second inhibitory area was not studied further, as the inhibition
was felt to be due to the presence of C3b in the column fractions . Fractions
representing the first peak of activity were pooled, concentrated, and subjected to
chromatography on CM-cellulose . C4b inactivator activity and also C3b inac-
tivator activity emerged from this column just before and overlapping transferrin
in fractions having a conductance of 3 to 6 mmhos/cm (Fig . 1) . Complete
separation from C3PA, which eluted considerably later, was achieved by using
this column . Hydroxyl apatite chromatography removed additional contami-NEIL R . COOPER
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Fic. 1 . Chromatographic steps in the isolation of C4b inactivator . The first peak of C4b
inactivator activity emerged from DE-32 cellulose (upper panel) at a conductance of 6
mmhos/cm as indicated. The active fractions were pooled, dialyzed, and applied to a CM-32
cellulose column (middle panel) . C4b inactivator eluted just before themain protein peak at a
conductance of 4 mmhos/cm as indicated . The active fractions were pooled, dialyzed, and
applied to an OH-apatite column (lower panel) from which C4b inactivator eluted at a
conductance of 6 mmhos/cm .
nants and reduced the contamination of transferrin which eluted before C4b and
Cab inactivator activities ; these came together at a conductance of 5.5-6.5
mmhos/cm . Although Cob inactivator was not pure at this stage, activity was not
detectable after additional chromatographic procedures designed to remove the
contaminating Ig and transferrin . Among the separatory procedures attempted
were chromatography on Sephadex G-200, QAE-Sephadex, and Biorex-70 .
Physicochemical Characteristics of C4b Inactivator . Ouchterlony analyses
showed the preparations to be unreactive with antisera to C1q, C3, C4, C5, and
C3 proactivator, but reactive with antisera to IgG, IgA and transferrin .
Polyacrylamide gel electrophoretic analysis ofa typical Cob inactivator prepara-
tion revealed three bands as shownin Fig . 2. The cathodal of these was due to IgG
while the anodal represented transferrin . As indicated in Fig. 2, Cob inactivator
activity migrated in parallel unstained gels in the position occupied by the
middle band . Although not shown, C3b inactivator activity was also evident in
these eluates .
Cob inactivator as well as C3b inactivator migrated as a,-globulin on
electrophoresis in agarose at pH 8.6 . Sucrose gradient ultracentrifugal analysis
indicated a sedimentation rate of 4.5S for Cob inactivator . Cob and Cab
inactivator activities eluted together with transferrin from Sephadex G-200
columns, indicating a diffusion coefficient ofapproximately 5 .3 x 10- ' cm 2/sec .
A mol wt of approximately 88,000 daltons was calculated from the S-rate and894
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diffusion coefficient . C4b- and Cab-inactivating activities were destroyed by
incubation with 1 x 10-2M DTT at pH 8.0 but not by 1 x 10 -2M DFP orPMSF,
100 ug/ml of soybean, lima bean, ovomucoid or kallikrein trypsin inhibitors, orby
5 ug/ml of isolated C1 inactivator, a 2-macroglobulin, a,-antitrypsin, or inter-a-
trypsin inhibitor .
Effect of C4b Inactivator on Cell-Bound C4b . Varying amounts of C4b
inactivator were incubated with 2 x 108 EAC14 in a total vol of 0.1 ml for 60 min
at 37 °C . After washing, active C4b remaining on the cells was assayed
hemolytically and by immune adherence . As indicated in Fig . 3, C4b inactivator
produced a dose-dependent loss in the hemolytic and immune adherence activity
of bound C4b . Parallel studies with EAC1423 prepared with limited amounts of
C4 which were immune adherence-negative at the EAC14 stage showed that the
C4b inactivator preparations also inactivated the hemolytic and immune
adherence activity of bound Cab . Similar studies performed with EAC1 [1251]C4
showed a dose-dependent reduction in cell-bound C4 radioactivity with 19% of
the total counts being dissociated by the largest amount of C4b inactivator
employed, 87 ug .
The relationship between inactivation of bound C4b activity and dissociation
FIG. 2. Mobility of C4b inactivator on electrophoresis in 6% polyacrylamide gels . C4b
inactivator was eluted from segments of a parallel unstained gel .
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FIG. 3 . Dose-dependent inactivation of the hemolytic and immune adherence activity of
cell-bound C4b by C4b inactivator . Hemolytic testing (A-A) showed 50% inactivation of a
limited amount of cell-bound C4b by 1.5 ug of C4b inactivator, while 50% inactivation of the
immune adherence activity(O-O) ofcells bearing a larger amount of C4b, approximately 5,000
molecules per cell with 10 jug of C4b inactivator .of radiolabeled C4 from cells was determined by periodic samplings at 37°C ofa
reaction mixture composed of EAC1 ( 1151]C4 and 46 ug of C4b inactivator . As
indicated in Fig . 4, immune adherence activity was rapidly lost, whereas C4
radioactivity was released from the cells at a considerably slower rate . This
difference in kinetics suggests that functional inactivation is not the direct result
of dissociation of C4b from the cells. A maximum of 70% of the bound C4
radioactivity could be removed after prolonged incubation (37°C, 24 h) with large
amounts of C4b inactivator . In order to determine whether the failure to
completely remove bound C4 was due to cleavage of the molecule with retention
of a fragment on the cell, [1151]C4 eluted from EAC1 [1151]C4 by C4b inactivator
was examined by sucrose gradient ultracentrifugation . As shown in Fig . 5, a 5.5S
s 20-
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FIG . 4 . Kinetic study of the ability of C4b inactivator to dissociate C4 radioactivity from
EAC1 [12511C4 and to inactivate C4b-dependent immune adherence activity .
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FIG . 5 . Sucrose gradient ultracentrif'ugal analysis of C4b and of [1251]C4 dissociated from
EAC1[1251]C4 by C4b inactivator. Marker proteins employed to determine the sedimenta-
tion rate were C1q, IgG, human serum albumin, and cytochrome C.896
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sedimentation rate was observed for C4 eluted by the action ofC4b inactivator in
contrast to the 9S rate observed for C4b, a finding which documents cleavage of
bound C4 by C4b inactivator .
Effect of C4b Inactivator on C4b in Solution .
￿
C4b was incubated with buffer
or with C4b inactivator for prolonged periods of time (up to 24 h) at 37°C . The
status of C4b was then examined by immunoelectrophoresis in agarose . A new
anodally migrating line reactive with anti-C4 appeared after treatment with C4b
inactivator. Residual C4b appeared to spur over this derivative line .
Effect of C2 on the Susceptibility of EAC14 to C4b Inactivator . EAC14,
bearing approximately 8,000 molecules of C4 per cell, were incubated with
various concentrations of oxidized humanC2 . After washing, batches ofEAC142
cells were incubated with C4b inactivator or with buffer for 60 min at 37°C,
washed again, and examined for immune adherence activity . EAC14 which had
not been incubated with C2 showed a decrease in immune adherence titer from 1
x 10'/ml to >3 x 10 a/ml aftertreatment with C4b inactivator as shown in Fig . 6.
In contrast, the ability of C4 inactivator to attack bound C4b was impaired by
the presence of cell-bound C2 . Thus, EAC142 prepared with the highest dose of
oxidized C2 were almost completely protected from C4b inactivator action . A
progressive increase in susceptibility to C4b inactivator was observed as the
amount of bound C2 was decreased as indicated in Fig . 6. Interestingly, the
presence of C2 on EAC14 did not affect the ability of the C4 to participate in
immune adherence, since EAC14 and the various batches of EAC142 had the
same immune adherence titer .
Effect of C4b and Cab on C4b Inactivator .
￿
Since C4b inactivator acted upon
C4b in free solution or on the surface of cells, it was considered likely that C4b in
solution would inhibit the attack of C4b inactivator on bound C4b by providing
C2 Input (Molecules per CelIx10'4 1
FIG. 6. Effect of C2 on the susceptibility of theEAC14to inactivation by C4b inactivator . Full
inactivation of cell-bound C4b immune adherence activity was obtained on treatment of
EAC14 and EAC142 bearing small amounts of cell-bound C2 with C4b inactivator . With
increasing amounts of cell bound C2, the cells became progressively more resistant to
inactivation by C4b inactivator . Cell bound C2 did not influence the reactivity of cell bound
C4b in immune adherence as shown by the identical titer of the various batches of EAC142 .NEIL R. COOPER
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additional substrate. Varying amounts of C4b were added to a mixture of C4b
inactivator and EAC14. After 60 min at 37°C the cells were washed, diluted, and
examined for immune adherence activity . In the control, which did not contain
C4b, C4b inactivator reduced the IA,,, titer of the cells from 1 x 10'/ml to >2 x
109/ml. The action of C4b inactivator on EAC14 was inhibited by the presence of
C4b as shown by an increase in the IAso titerto 1.25 x 108/ml, 2.5 x 10$/ml, and 1
x 109/ml when 145, 72, and 36 Fig of C4b, respectively were included. In the same
experiment C3b was also found to inhibit the action of C4b inactivator on
EAC14. IA,,, titers of 1 x 10'/ml, 3 x 10'/ml, 2 x 108/ml, and 1 x 109/ml were
obtained when 96, 48, 24, and 12 leg of C3b, respectively, were present during the
reaction of Cob inactivator with EAC14.
Lack of Reactivity of C4b Inactivator-Treated Cell-Bound C4b with
Conglutinin. C3b inactivator has been termed KAF or conglutinogen-activat-
ing factor because of its ability to render bound Cab reactive with bovine
conglutinin (3). The following experiment was performed to determine whether
bound C4b was also capable of acting as a conglutinogen after treatment with
C4b inactivator. EAC14 were incubated with dilutions of C4b inactivator for 60
min at 37°C after which purified bovine conglutinin (300 Ag/ml) was added.
After 30 min of incubation at 37 °C the cells were allowed to settle and the pat-
tern of the sedimented erythrocytes determined. No agglutination (conglutina-
tion) of the cells and thus no reactivity of the EAC14 with conglutinin was evi-
dent. In parallel experiments with EAC1423, the same amount of conglutinin
strongly agglutinated the cells to a 1:800 dilution of the C4b inactivator prep-
aration. Thus, C4b is unable to act as a conglutinogen after treatment with C4b
inactivator.
Analysis of the Effect of C4b Inactivator on the Subunit Structure of C4.
￿
In
order to determine the nature of the attack on the C4 molecule by C4b
inactivator, radiolabeled preparations of C4 and C4b were incubated with C4b
inactivator. Urea, SDS, and DTT were added, and the mixtures were subjected
to electrophoresis in SDS-polyacrylamide gels . The gels were sectioned and the
segments analyzed for radioactivity. The basic three polypeptide chain structure
of C4 was not found to be altered by incubation with C4b inactivator. Mot wt for
the a-, 0-, and y-chains were 96,000, 74,000 and 32,000 daltons, respectively,
in good agreement with earlier studies (19) . In contrast, the structure of C4b
was markedly altered by C4b inactivator. In the experiment depicted in Fig. 7,
long SDS-polyacrylamide gels were employed in order to better define the ef-
fects. The average mot wt obtained in these studies for the a'-, ,Q- and .y-chains
were 84,000 (range 80,000-87,000), 76,000 (70,000-79,000), and 32,000 (29,000-
36,000) daltons, respectively (Fig. 7, upper panel) . As shown in the central
panel, C4b inactivator markedly diminished the amount of radioactivity asso-
ciated with the position of the a'-chain of the molecule. In addition, a new peak
having an average mot wt of 49,000 (46,000-52,000) daltons appeared, and the
percentage of total radioactivity present in the 30,000-35,000 dalton range
occupied by the ti-chain increased. Furthermore, the percentage of total radio-
activity present in the 49,000 dalton peak plus the increment in radioactivity
of the 30,000-35,000 dalton range approximately equalled the percentage of
radioactivity missing from the a'-peak. From these studies it is evident that898
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FIG . 7 . Effect of C4b inactivator on the structure of C4b. C4b was incubated alone (upper
panel), with apurified C4binactivator preparation (middle panel) or with acrudepreparation
of C4b inactivator (lower panel) after which the mixtures were analyzed by electrophoresis in
SDS acrylamide gels . The purified C4b inactivator preparation produced a decrease in the
amount of radioactivity associated with the a'-chain of C4b (middle panel) . The radioactivity
missing from the position ofthe a'-chain was accounted forby a cleavage producthaving amol
wt of 49,000 daltons and by an increase in the percentage of the total radioactivity present in
the 30,000-35,000 dalton range occupied by the 1'-chain . Crude C4b inactivator preparations
(lower panel) in addition cleaved the /3-chain into a majorfragment having a mol wt of 67,000
daltons and a minor fragment or fragments having a mol wt of less than 20,000 daltons .
C4b inactivator cleaves the a'-polypeptide chain of C4b into fragments having
mol wt of 40,000 daltons and approximately 30,000-35,000 daltons . Since no
smaller fragments bearing radioactivity were detected, it may be assumed that
C4b inactivator cleaves the a'-chain at a single site producing two fragments
having mol wt of 49,000 and 35,000 daltons, respectively . This structural altera-
tion undoubtedly represents the mechanism by which C4b inactivator destroys
the functional activity of C4b .
A second cleavage in the 0-chain of the C4b molecule (Fig . 7, lower panel) was
produced by crude C4b inactivator preparations that had only been subjected to
the first step of the isolation procedure . This second cleavage was never observed
with the more highly purified C4b inactivator preparations . The second cleavage
generated a large fragment having a ml wt of 67,000 daltons and a smaller
fragment or fragments which had a mol wt of less than 20,000 daltons. This
secondary cleavage reaction was not essential for inactivation of C4b functional
activity since preparations of C4b inactivator which produced only cleavage of
the a'-chain rendered bound C4b functionally inactive . In order to determinewhich fragment of the a'-polypeptide chain remained on the cell after treatment
with Cab inactivator, an experiment with Forssman antigen particles sensitized
with antibody, C1, and [ 1251]C4 was performed. FAC1 [1251]C4 complexes were
incubated with a crude preparation of C4b inactivator for 60 min at 37°C. After
washing, the adherent C4b fragment was dissociated by SDS and analyzed by
SDS acrylamide gels. Most of the radioactivity was present in a peak having a
mol wt of 35,000 daltons as indicated in Fig. 8. A minor peak with a mol wt of
45,000 daltons was also observed . This study indicates that the smaller fragment
of the a'-chain remained adherent to complexes after treatment with C4b
inactivator and thus may be termed C4d in analogy to the comparable fragment
of C3 . In the same study, the C4 fragment dissociated from FAC [1251]C4 by C4b
inactivator migrated as a single peak of radioactivity on electrophoresis in
SDS acrylamide gels in the absence of DTT. After reduction and analysis of
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FiG. 8. SDS acrylamide gel electrophoretic analysis of the fragment of C4 remaining bound to
FAC1['z5I]C4 after extensive treatment with C4b inactivator. The adherent fragment
dissociated by SDS had a mol wt of 35,000 daltons. In addition, a second minor peak having a
mol wt of 45,000 daltons was observed.
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this fragment, which may be termed C4c, in SDS acrylamide gels, two broad
peaks of radioactivity were observed which had mol wt at their highest points of
64,000 and 29,000 daltons, respectively .
Discussion
This paper documents the existence of an inactivator of C4b in normal human
serum. The active principle was isolated in a partially purified form from serum
and found to be a 01-globulin with an approximate mol wt of 88,000 daltons. C4b
inactivator actedonly upon the activated fourth component of complement, C4b;
native C4 was completely resistant to its action. Incubation of bound C4b with
C4b inactivator resulted in a time and dose-dependent inactivation of the
hemolytic activity of bound C4b. In addition, the ability of bound C4b to interact
with erythrocytes or lymphocytes (29) which possess receptors for C4b, was also
lost.
C4b inactivator abrogated the biological activity of C4b by cleaving it into two
fragments which may be termed C4c and C4d in analogy to the terminology used900
￿
MECHANISM OF ACTION OF Cob INACTIVATOR
for C3 . Cleavage of the molecule could be demonstrated directly on immunoelec-
trophoretic analysis of inactivator-treated C4b . The fragments separated after
treatment of cell-bound C4b with C4b inactivator followed by prolonged
incubation, since C4c was dissociated from the cells under these conditions while
C4d remained adherent . C4c was found to sediment as a 5.5S protein in sucrose
gradients in contrast to the 9S rate observed for C4b . C4d remaining adherent to
the cells was detected by residual radioactivity after extensive treatment with
C4b inactivator and, although not described here, by agglutination of the treated
cells with antisera which detected the fragment .
SDS-polyacrylamide gel analyses of inactivator-treated C4b revealed a single
cleavage site located in the a'-polypeptide chain of the molecule . Cleavage at this
site represents the mechanism of inactivation of the functional activity of C4b
since the more purified preparations of C4b inactivator produced only this
cleavage . The two fragments of the a'-chain, termed a 2 and a 3 , had mol wt of
35,000 and 49,000 daltons, respectively (Table I) . The a 2-fragment was identified
as C4d by elution from FAC1 [ 111I]C4 extensively treated with C4b inactivator .
TABLE I
Fragments of C4 and of C4 Polypeptide Chains
C4a = a,
C4b = a' (az + a 9 ) + 0 + 'y
C4c=a,+,B+y
C4c' =a 2 + Oz + 7
C4d = a2
-y-Chain (32,000)
C4c is thus composed of the remaining portion of the a-chain, a 3 , plus the a- and
-y-chains . Since C4b inactivator treatment alone dissociated C4b, the a 2-frag-
ment is not disulfide-linked to the remainder of the molecule . The three
polypeptide chains of C4c, however, are linked by disulfide bridges since C4c
sediments in sucrose gradients and migrates in polyacrylamide gels as a single
peak of radioactivity in the absence of reducing agents . These concepts are
illustrated schematically in the model for C4 structure shown in Fig . 9 .
Crude preparations of C4b inactivator produced, in addition, a second cleavage in the
,8-chain of C4b . A reduction in the mol wt of the 0-chain from 76,000 daltons to 67,000
daltons and the concomitant appearance of a small fragment, or fragments, migrating
close to the buffer front were observed on treatment of C4b with crude C4b inactivator
preparations . Although it is not clear that this was a single cleavage, it is depicted as such
in the model (Fig . 9) . This cleavage was not essential for inactivation as considered above .
It is not known whether this secondary cleavage was also produced by C4b inactivator,
since the crude preparations were considerably more active with regard to hemolytic and
immune adherence inactivation than the more highly purified preparations . The crude
a-Chain (90,000) R-Chain (76,000)
a, (6,000) 01(91000)
a2 (35,000) ,12 (67,000)
a, (49,000)C4a C46
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FIG. 9 . Model depicting the effects of C4b inactivator on the polypeptide chain structure of
C4b .
preparations were also unable to cleave native C4 and, furthermore, cleavage of the
0-chain was not observed unless the a-polypeptide chain was fragmented . While these
findings suggest that the secondary cleavage resulted from the action ofC4b inactivator, it
is also possible that it was produced by a contaminant enzyme that acted on a susceptible
site in the ,Q-chain exposed by cleavage of the a'-chain .
Certain structural correlates ofC4 functional activities are evident from these studies .
First, the labile binding site which enables C4b to bind to cells or complexes after
activation is located in the a 2-fragment of the a'-polypeptide chain, since this fragment
remains adherent to cells or complexes after the action of C4b inactivator . Second, the
receptor for C2a on the C4b molecule is located on or closely proximate to the a 2-a 3
junction in the a'-chain, because the presence of C2a on C4b protects it from cleavage by
C4b inactivator. Third, the stable binding site by which C4b attaches to cells bearing
receptors for this fragment is spatially removed from theC2 binding site, since attachment
of C2a to C4b has no effect on C4b immune adherence activity . Whether it is in C4c or
represents a site lost by the action of C4b inactivator on C4b cannot be determined at
present .
C4U Inactivator 1
1 7 R1 S P2 S
The structural and functional similarities of C4 and C3 are also emphasized by
these studies . In addition to the analogous mechanism of activation with
cleavage of the a-chain of each molecule and release of a small fragment, the
similarities in structure, and the presence on both molecules ofsites reactive with
cells bearing receptors for the b-fragments of each, the present study shows that
C4b, like C3b, is susceptible to the action of a serum enzyme which inactivates
the biological activities of the molecules . Among the several differences, however,
are the presence of an additional polypeptide chain in C4, the 'y-chain, and the
inabilityofC4b to serve asa conglutinogen after treatment with its inactivator.
The present studies do not definitely determine whether C4b and C3b inacti-
vators are identical, although this is probable . As pointed out, both activities have
the same distribution on each of the chromatographic steps employed in isolation
and both are eluted from acrylamide gels in an identical distribution . They also
have the same physicochemical properties, and each is susceptible to inactiva-
tion by reduction, but resistant to inactivation by a number of chemical and phys-
ical agents . The strongest evidence, however, for identity comes from the fact
that C3b, as well as C4b, is able to inhibit the action of C4b inactivator on bound
C4 . However, definitive proofof identity must await the availability of antisera to
each active principle .902
￿
MECHANISM OF ACTION OF Cob INACTIVATOR
Summary
A complement regulatory principle, C4b inactivator, was isolated in a partially
purified form from normal human serum. The C4b inactivator, a ,d,-globulin with
an approximate mol wt of 88,000 daltons, and which may be identical to C3b
inactivator, cleaved C4b in free solution or on the surface of cells and rendered it
unable to participate in hemolytic reactions or to interact with cells having
receptors for C4b. C4b inactivator functioned by cleaving the a'-polypeptide
chain of C4b at a single site which was sufficient to dissociate the molecule into
two fragments, C4c and C4d, and to inactivate it biological function. Certain
structural correlates of C4 functions deriving from these studies are discussed
and a model for C4 structure based on these findings is presented.
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